Inventiva S.A.
NASDAQ:IVABiotechnology
+$0.02 today
- Market cap
- $167.38M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
Volume 2.04M
Average 0.45M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Inventiva S.A.
NASDAQ:IVA
Intrinsic Alpha fair value
Locked
Current Price
$3.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -28.3% | +168.7% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -28.3% over three years. Forward estimates point to Revenue at +168.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc. NASDAQ:EPRX | $548.02M | $8.15 | Not rated | -8.5 | +3.92% |
Avalo Therapeutics, Inc. NASDAQ:AVTX | $448.71M | $7.76 | Not rated | -3.6 | -60.39% |
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | $435.76M | $7.25 | Not rated | -2.8 | +64.78% |
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | $320.09M | $10.99 | Not rated | -4.3 | -29.69% |
Nautilus Biotechnology, Inc. NASDAQ:NAUT | $295.50M | $2.32 | Not rated | -4.9 | +6.79% |
Cartesian Therapeutics, Inc. NASDAQ:RNAC | $193.69M | $6.35 | Not rated | -1.7 | -19.69% |
Invivyd, Inc. NASDAQ:IVVD | $171.58M | $0.58 | Not rated | -3.9 | -79.74% |
Tenaya Therapeutics, Inc. NASDAQ:TNYA | $79.59M | $0.35 | Not rated | -1.3 | -74.78% |
Caribou Biosciences, Inc. NASDAQ:CRBU | $39.10M | $0.36 | Not rated | -1.1 | -73.83% |
Continue the stock analysis
Jump to another research area for this company.